News
Market and company headlines
ZTSAll
Loading
17:00Oct 231 Story
10:00Oct 211 Story
13:00-17:00Oct 202 Stories
Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
PARSIPPANY, N.J., October 20, 2026--Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections
Zoetis: Weakening Fundamentals Overshadow The Discount
Zoetis (ZTS) rated sell as growth slows and guidance falls. Read the latest analysis on the stock here.
04:00Oct 201 Story
01:00-12:00Oct 162 Stories
Zoetis’ Valuation Has Fallen Sharply, but Has the Market Overreacted?
The investment case for Zoetis Inc. (NYSE:ZTS) has changed significantly since declining demand in its U.S. companion-animal business has put pressure on earnings forecasts and affected the price of its shares. As a company in the animal health sector, Zoetis produces medicines, vaccines, and diagnostic products for both pets and livestock, and the wide range […]
Goldman Sachs Initiates Coverage On Zoetis with Neutral Rating, Announces Price Target of $74
Goldman Sachs analyst Matt Dellatorre initiates coverage on Zoetis (NYSE:ZTS) with a Neutral rating and announces Price Target of $74.
09:00-13:00Oct 152 Stories
Zoetis (ZTS) Hit by Guidance Cuts, Met with Market Shrug
Middle Coast Investing, an investment advisor firm, released its second-quarter 2026 investor letter. The letter can be downloaded here. Market breadth in Q3 2026 reviews shows dominance by a few sectors, with S&P 500 stocks averaging a 9.7% return and only 40.55% above their 200-day moving average. Key themes include AI, inflation, and the U.S.-Iran conflict, […]
3 Reasons ZTS is Risky and 1 Stock to Buy Instead
Zoetis has gotten torched over the last six months - since April 2026, its stock price has dropped 37.6% to $75.34 per share. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
03:00-08:00Oct 142 Stories
Zoetis (NYSE:ZTS): A Quality Investing Case Study in Animal Health
Zoetis quality investing analysis: high ROIC, strong cash flow, low debt, reasonable valuation, but revenue growth lags Caviar Cruise screen criteria.
Zoetis (ZTS) Board Update And Dividend Keep Undervalued Narrative In Focus
Board appointment and dividend set the stage for Zoetis Zoetis (ZTS) has given investors fresh governance and income headlines in October, with Iris Knobloch joining the Board and a fourth quarter dividend of $0.53 per share affirmed. For context, Zoetis shares trade at US$74.30 after a 4.16% 7-day share price gain. However, the 1-year total shareholder return has declined 47.21% and the 5-year total shareholder return is down 61.56%, suggesting recent momentum is tentative against a weaker...
07:00-13:00Oct 132 Stories
Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at branded pharmaceuticals stocks, starting with Zoetis (NYSE:ZTS).
Zoetis Appoints Iris Knobloch to its Board of Directors
PARSIPPANY, N.J., October 13, 2026--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With decades of experience across global media and consumer businesses, Ms. Knobloch brings a distinct combination of international leadership, proven public company board experience across financial services, hospitality and media, and deep consumer and digital expertise to the Zoetis Board. She currently serves on the boards of
08:00Oct 111 Story
17:00Oct 91 Story
17:00-23:00Oct 12 Stories
Zoetis (ZTS) Has a Huge Animal Health Moat. Is It Starting to Crack?
Zoetis Inc. (NYSE:ZTS) has built one of the strongest franchises in animal health. Its products are used by veterinarians around the world; its portfolio spans medicines, vaccines, and diagnostics, and its research capabilities have helped establish entire categories of treatment. But a moat is only valuable if it protects market share and pricing power when […]
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why
Zoetis (ZTS) reached $69.1 at the closing of the latest trading day, reflecting a -1.05% change compared to its last close.
02:00Sep 301 Story
05:00Sep 251 Story
07:00-18:00Sep 242 Stories
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, Zoetis (ZTS) closed at $70.27, indicating a -1.87% shift from the previous trading day.
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results
PARSIPPANY, N.J., September 24, 2026--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief Operating Officer Jay Saccaro will review third quarter 2026 financial results and respond to questions from financial analysts.
06:00Sep 241 Story
05:00-23:00Sep 212 Stories
'Big Short' Michael Burry Tunes Out AI ‘Woo-Hoos’ — Finds Opportunity In Copper, QXO And 3 More Stocks
Burry’s indirect AI bet is ERO, saying that data-center construction will intensify copper demand while new mines take 18 years to reach production.
1 Mid-Cap Stock with Exciting Potential and 2 We Turn Down
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
06:00-19:00Sep 182 Stories
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note
Zoetis (ZTS) closed at $71.4 in the latest trading session, marking a -2.22% move from the prior day.
Zoetis: The Worst May Be Priced In
Zoetis is still generating the bigger part of its revenue in the United States, the picture for the overall market is different. Read why ZTS stock is a buy.
01:00-05:00Sep 182 Stories
Zoetis (ZTS) Stock Fair Value Falls After Mixed Analyst Cuts And Softer Growth Views
Zoetis is back in focus after analysts cut their fair value estimate from US$114.76 to US$96.00, a reduction of around 16% that resets expectations around what the stock might be worth. This shift lines up with more mixed analyst commentary, where many firms are trimming price targets and some are also dialing back their ratings as they reassess clinic trends, competition and pricing. Read on to see what is driving the updated narrative and how you can track the next moves in Zoetis. Stay...
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
Zoetis (NYSE:ZTS) executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in dermatology and parasiticides. Speaking at a Morgan Stanley conference, CEO Kri
01:00-04:00Sep 172 Stories
Zoetis: Companion Animal Weakness Keeps Me On The Sidelines
Zoetis (ZTS) outlook: Q2 2026 revenue flat, U.S. companion animal sales -11%.
Zoetis: An Undervalued Compounder Hiding In Plain Sight
Zoetis faces near-term pressure from weaker US companion animal demand, increased competition, and margin compression. Learn more about ZTS stock now.
00:00Sep 171 Story
13:00Sep 141 Story
06:00Sep 71 Story
07:00Sep 31 Story
08:00Sep 21 Story
06:00Sep 11 Story
01:00Aug 311 Story
04:00Aug 301 Story
15:00Aug 271 Story
06:00Aug 251 Story
10:00Aug 211 Story
05:00Aug 201 Story
12:00-14:00Aug 192 Stories
Zoetis (ZTS) Stock Still Looks Cheap After a 62% Slide
Zoetis stock has had a tough run over the last few years, yet the current valuation checks suggest the shares may now be pricing in a lot of that bad news. After a prolonged slide, the question is whether the current market price properly reflects Zoetis' earnings power and risks. Over the past 5 years, Zoetis shareholders have seen the share price decline about 61.8%, which points to a significant reset in expectations. Recent investor focus is on how competition and softer pet care...
Is Zoetis’ Lowered 2026 Outlook and Simparica Trio EUA Altering The Investment Case For Zoetis (ZTS)?
Zoetis recently received an Emergency Use Authorization from the U.S. FDA for its Simparica Trio chewable to treat life-threatening New World screwworm infestations in dogs and puppies, while also appointing experienced healthcare executive Jay Saccaro as its new Chief Financial Officer and Chief Operating Officer. At the same time, Zoetis lowered its full-year 2026 revenue and earnings guidance, signaling a more cautious outlook even as it expands the clinical reach of one of its flagship...
10:00Aug 191 Story
00:00Aug 181 Story
04:00Aug 161 Story
06:00-11:00Aug 142 Stories
Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense
Zoetis (ZTS) trades at 12x forward earnings with a ~3% yield after a big drawdownâsee why its margins, buybacks, and value setup make it a Buy. Read the full analysis here.
MOO: Farm Cycle Recovery And Long Term Food Security
Explore VanEck Agribusiness ETF (MOO): global ag exposure, discounted valuation, dividends, and catalysts vs risks.
15:00-17:00Aug 132 Stories
Michael Burry-Backed ZTS Stock Climbs Following FDA Green Light For Dog Pill Against Screwworm
The FDA authorized Zoetis’s Simparica TRIO—already sold since 2020 for heartworm, fleas and ticks—for treating New World screwworm in dogs and puppies.
Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies
PARSIPPANY, N.J., August 13, 2026--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax, commonly called New World screwworm (NWS), feed on living tissues, such as open wounds, of animals including livestock, wildlife and pets, and can inflict dam
08:00-10:00Aug 132 Stories
FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies
https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-treat-new-world-screwworm-dogs-and-puppies
Zoetis (ZTS) Q2 2026 Earnings Call Transcript
U.S. companion animal demand weakened, but livestock and diagnostics surged.